文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

首例人体经心尖搏动心脏室间隔心肌切除术治疗肥厚型梗阻性心肌病

First-in-Human Transapical Beating-Heart Septal Myectomy in Patients With Hypertrophic Obstructive Cardiomyopathy.
PubMed 文献 · J Am Coll Cardiol · 2023-01-01

该首例人体试验纳入47例药物难治性症状的肥厚型梗阻性心肌病患者,采用经心尖搏动心脏室间隔心肌切除术(TA-BSM),在超声引导下经小切口、无需体外循环完成。46例随访3个月,42例达到手术成功标准。最大左心室流出道压差从基线86 mm Hg降至3个月19 mm Hg,二尖瓣反流≤1+的患者从基线3例增至45例。

要点

  • TA-BSM无需体外循环,经心尖小切口在超声引导下完成室间隔心肌切除。
  • 3个月随访时42/46例达到手术成功标准(静息/激发LVOT压差<30/50 mm Hg且MR≤1+)。
  • 最大LVOT压差从基线86 mm Hg降至3个月19 mm Hg,MR≤1+患者从3例增至45例。

核心结论

  • TA-BSM是治疗异质性肥厚型梗阻性心肌病安全有效的微创室间隔减容手术。
  • 与传统室间隔心肌切除术相比,TA-BSM可实时评估指导切除并减少手术创伤。

研究设计与样本

  • 首例人体前瞻性试验,纳入47例药物难治性致残症状的肥厚型梗阻性心肌病患者,年龄12至77岁。
  • TA-BSM经小切口在超声心动图引导下使用搏动心脏心肌切除装置完成,无需体外循环。
  • 主要结局为3个月随访时静息/激发LVOT压差<30/50 mm Hg且残余MR≤1+(4+分级)定义的手术成功。

主要发现

  • 46例随访3个月,42例达到手术成功标准。
  • 最大LVOT压差从基线86 mm Hg(IQR 67-114)降至3个月19 mm Hg(IQR 14-28)。
  • MR≤1+的患者从基线3例增至3个月45例。
  • 1例术后第10天因非器械相关原因死亡;其他主要不良事件包括1例迟发性室间隔穿孔和1例术中左心室心尖撕裂。

关键数值与推荐

  • 手术成功定义:3个月随访时静息/激发LVOT压差<30/50 mm Hg且残余MR≤1+(4+分级)。

临床怎么用

  • 对于药物难治性症状的肥厚型梗阻性心肌病患者,TA-BSM可在无需体外循环下实现室间隔减容。
  • 术中可实时评估指导切除范围,以充分解除LVOT梗阻和二尖瓣反流。

局限性

  • 首例人体试验,样本量有限(47例),随访时间仅3个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To simplify surgical septal reduction therapy for hypertrophic obstructive cardiomyopathy (HOCM), we developed a novel transapical beating-heart septal myectomy (TA-BSM) procedure. OBJECTIVES: In this study, we sought to evaluate the clinical utility of TA-BSM in a first-in-human trial. METHODS: Patients with HOCM were enrolled if they presented with drug-refractory disabling symptoms. TA-BSM was performed via minithoracotomy with the use of our beating-heart myectomy device under echocardiographic guidance, without the use of cardiopulmonary bypass. Repeated resections were performed to tailor the extent of the septal myectomy for sufficient abolishment of left ventricular outflow tract (LVOT) obstruction and mitral regurgitation (MR). The primary outcome measure was procedural success, defined by resting/provoked LVOT gradient <30/50 mm Hg and residual MR grade ≤1+ (of 4+) at 3-month follow-up. RESULTS: A total of 47 patients aged 12 to 77 years were enrolled. Of the 46 patients who were followed for 3 months, 42 achieved procedural success. The maximal LVOT gradient decreased from 86 mm Hg (IQR: 67-114 mm Hg) at baseline to 19 mm Hg (IQR: 14-28 mm Hg) at 3 months. MR grade was ≤1+ in 3 patients at baseline and in 45 patients at 3 months. One patient died on postoperative day 10 owing to device-unrelated reasons. Other major adverse events included 1 delayed ventricular septal perforation and 1 intraoperative left ventricular apical tear. CONCLUSIONS: TA-BSM is a safe and efficient minimally invasive procedure for septal reduction of heterogeneous HOCM. Compared with conventional septal myectomy, TA-BSM provides real-time evaluation to guide resection while reducing surgical trauma. (Transapical Beating-Heart Septal Myectomy in Patients With Hypertrophic Obstructive Cardiomyopathy; NCT05332691).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Fang J, Liu Y, Zhu Y, et al. First-in-Human Transapical Beating-Heart Septal Myectomy in Patients With Hypertrophic Obstructive Cardiomyopathy. J Am Coll Cardiol. 2023. PMID: 37558369. doi:10.1016/j.jacc.2023.05.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。